January 16, 2017Expert Review of Molecular Diagnostics
Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy
Why the study?
Does biomarker-guided monitoring (cardiac troponin) and targeted preventive therapy improve clinical outcomes and prevent cardiotoxicity in patients undergoing cancer therapy?
Population
Patients undergoing cancer therapy at risk of cardiotoxicity
Comparison
Biomarker-guided monitoring and targeted… vs Standard monitoring of cardiac function
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May enable earlier cardiotoxicity detection before functional decline; leaves open prospective validation before clinical adoption.
Structured PICO
Does biomarker-guided monitoring (cardiac troponin) and targeted preventive therapy improve clinical outcomes and prevent cardiotoxicity in patients undergoing cancer therapy?
P
Population
Patients undergoing cancer therapy at risk of cardiotoxicity
I
Intervention
Biomarker-guided monitoring (specifically cardiac troponin) and targeted preventive therapy with ACE inhibitors (e.g., enalapril)
C
Comparator
Standard monitoring of cardiac function (detecting functional impairment after it has occurred)
O
Outcome
Early identification of cardiotoxicity and prevention of cancer therapy-induced left ventricular dysfunction and associated clinical complications
Biomarker-guided monitoring using cardiac troponin allows for early identification of cancer patients at high risk for cardiotoxicity, enabling targeted cardioprotective therapy with ACE inhibitors.
Limitations
- Some limitations to a routinely use of biomarkers still exist
Cite This Study
Cardinale et al. (2017) studied this question.